Heart failure mortality according to acute variations in N-terminal pro B-type natriuretic peptide and cystatin C levels

被引:12
|
作者
Carrasco-Sanchez, Francisco J. [1 ]
Perez-Calvo, Juan I. [2 ]
Morales-Rull, Jose L. [2 ]
Galisteo-Almeda, Luis [3 ]
Paez-Rubio, Inmaculada [1 ]
Baron-Franco, Bosco [1 ]
Aguayo-Canela, Mariano [1 ]
Pujol-De la llave, Emilio [1 ]
机构
[1] Hosp Juan Ramon Jimenez, Dept Internal Med, Huelva 21005, Spain
[2] Hosp Clin Univ Lozano Blesa, Dept Internal Med, Zaragoza, Spain
[3] Hosp Juan Ramon Jimenez, Dept Clin Chem & Lab Med, Huelva 21005, Spain
关键词
variations; mortality; cystatin C; heart failure; N-terminal pro B-type natriuretic peptide; prognosis; PROGNOSTIC VALUE; RENAL-FUNCTION; SERUM CREATININE; ADMISSION; OUTCOMES; TRIAL; METAANALYSIS; THERAPY; MARKERS; EVENTS;
D O I
10.2459/JCM.0b013e3283654bab
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim Changes in N-terminal pro B-type natriuretic peptide (NT-proBNP) levels and cystatin C (CysC) are predictors of adverse outcomes in acute heart failure. This study assess whether NT-proBNP variations might provide independent information in addition to that obtained from CysC levels. Methods NT-proBNP levels were assessed in patients admitted due to acute heart failure using an observational study. Patients were classified as follows: group 1, those with a decrease in NT-proBNP levels of at least 30% from admission to 4 weeks after discharge; group 2, those with no significant changes in levels; and group 3, those who showed an increase in NT-proBNP of 30%. A multivariable Cox regression model and c-statistics were used. The primary end-point was all-cause mortality at 1-year follow-up. Results A total of 195 patients completed the follow-up. The mortality rate reached 20.5% (40 patients); 14 out of the 32 in group 3. The cumulative incidence of death, according to the change in NT-proBNP and Kaplan-Meier analysis, showed a significant increase in group 3 (log-rank P = 0.004). In the multivariable analysis, NT-proBNP variation for group 3 (hazard ratio 4.27; P <0.001) and for group 2 (hazard ratio 2.19; P = 0.043) in comparison with group 1 were independently associated with all-cause mortality, as well as anemia, hyponatremia, and admission CysC levels. Patients in group 3, and those with levels of serum CysC above the median, were also associated with slight increase in mortality. Conclusion An increase of at least 30% in NT-proBNP levels after hospitalization is related to all-cause mortality in patients with acute heart failure and provides supplementary prognostic information in patients with high levels of CysC. A decrease in NT-proBNP of at least 30% is a desirable target to achieve.
引用
收藏
页码:115 / 121
页数:7
相关论文
共 50 条
  • [41] Implication of sacubitril/valsartan on N-terminal pro B-type natriuretic peptide levels in hypertensive patients
    Imamura, Teruhiko
    Kinugawa, Koichiro
    ANNALS OF PALLIATIVE MEDICINE, 2022, 11 (09) : 2856 - 2861
  • [42] Plasma atrial natriuretic peptide and N-terminal pro B-type natriuretic peptide concentrations in dogs with right-sided congestive heart failure
    Kanno, Nobuyuki
    Hori, Yasutomo
    Hidaka, Yuichi
    Chikazawa, Seishiro
    Kanai, Kazutaka
    Hoshi, Fumio
    Itoh, Naoyuki
    JOURNAL OF VETERINARY MEDICAL SCIENCE, 2016, 78 (04): : 535 - 542
  • [43] N-terminal pro B-Type natriuretic peptide (N-BNP) levels in cystic fibrosis patients
    Ben Tov, Amir
    Paret, Gideon
    Sela, Ben-Ami
    Blau, Hannah
    Hegesh, Julius
    Efrati, Ori
    Yahav, Yaacov
    Augarten, Arie
    PEDIATRIC PULMONOLOGY, 2007, 42 (08) : 699 - 703
  • [44] Usefulness of B-Type Natriuretic Peptide and N-Terminal Pro-B-Type Natriuretic Peptide as Biomarkers for Heart Failure in Young Children With Single Ventricle Congenital Heart Disease
    Lowenthal, Alexander
    Camacho, Benjamin Villareal
    Lowenthal, Shiri
    Natal-Hernandez, Luz
    Liszewski, Walter
    Hills, Nancy K.
    Fineman, Jeffrey R.
    Bernstein, Harold S.
    AMERICAN JOURNAL OF CARDIOLOGY, 2012, 109 (06): : 866 - 872
  • [45] High levels of N-terminal pro B-type natriuretic peptide are associated with ST resolution failure after reperfusion for acute myocardial infarction
    Lorgis, L.
    Zeller, M.
    Dentan, G.
    Sicard, P.
    Jolak, M.
    L'Huillier, I.
    Vincent-Martin, M.
    Beer, J. C.
    Makki, H.
    Gambert, P.
    Cottin, Y.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2007, 100 (04) : 211 - 216
  • [46] N-terminal Pro B-type Natriuretic Peptide in the Early Evaluation of Suspected Acute Myocardial Infarction
    Haaf, Philip
    Balmelli, Cathrin
    Reichlin, Tobias
    Twerenbold, Raphael
    Reiter, Miriam
    Meissner, Julia
    Schaub, Nora
    Stelzig, Claudia
    Freese, Michael
    Paniz, Patricia
    Meune, Christophe
    Drexler, Beatrice
    Freidank, Heike
    Winkler, Katrin
    Hochholzer, Willibald
    Mueller, Christian
    AMERICAN JOURNAL OF MEDICINE, 2011, 124 (08): : 731 - 739
  • [47] Acute on chronic heart failure-Which variations on B-type natriuretic peptide levels?
    Bettencourt, Paulo
    Chora, Ines
    Silva, Filipa
    Lourenco, Patricia
    Peacock, W. Frank
    JOURNAL OF THE AMERICAN COLLEGE OF EMERGENCY PHYSICIANS OPEN, 2021, 2 (03)
  • [48] B-type natriuretic peptide serum levels in acute heart failure
    Filippatos, GS
    Anker, SD
    Kardaras, F
    EUROPEAN HEART JOURNAL, 2004, 25 (12) : 1085 - 1085
  • [49] N-terminal B-type natriuretic peptide levels in pediatric patients with congestive heart failure undergoing cardiac surgery
    Walsh, Rowan
    Boyer, Clark
    LaCorte, Jared
    Parnell, Vincent
    Sison, Cristina
    Chowdhury, Devyani
    Ojamaa, Kaie
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2008, 135 (01): : 98 - 105
  • [50] B-type natriuretic peptide and N-terminal pro-BNP in the acute phase of Kawasaki disease
    Satoru Iwashima
    Takamichi Ishikawa
    World Journal of Pediatrics, 2013, 9 : 239 - 244